-
20 May 2024 Job Information Organisation/Company University of Oslo Research Field Medical sciences Researcher Profile Recognised Researcher (R2) Country Norway Application Deadline 2 Jun 2024 - 23
-
2nd June 2024 Languages English English English Campus Ahus Postdoctoral fellowship in epidemiology /biostatistics/medical statistics Apply for this job See advertisement Job description Applicants
-
26 Apr 2024 Job Information Organisation/Company University of Oslo Research Field Medical sciences Researcher Profile Established Researcher (R3) Country Norway Application Deadline 31 May 2024
-
18 Apr 2024 Job Information Organisation/Company University of Oslo Research Field Medical sciences Researcher Profile Recognised Researcher (R2) Country Norway Application Deadline 8 May 2024 - 23
-
of Boccara (Norwegian Centre for Molecular Medicine – ERC 2023 – Nature Comm 2022, Science 2019) and Knævelsrud (Institute for Basic medical sciences – ERC 2022 – iScience 2023, Nature Comm 2016), the postdoc
-
(Germany), and All India Institute of Medical Sciences (Delhi, India). As part of the project, the candidate will potentially spend short-term visits (up to 2 months) at our collaboration partners' labs
-
22 Apr 2024 Job Information Organisation/Company University of Oslo Research Field Medical sciences Researcher Profile Recognised Researcher (R2) Country Norway Application Deadline 15 May 2024 - 23
-
Universities of Aarhus (Denmark), Helsinki (Finland), Oslo (Norway) and Umeå (Sweden) | Denmark, Maine | United States | about 2 months ago
and the European Molecular Biology Laboratory (EMBL) , with complementary research expertise at the forefront of molecular medicine research. With the NORPOD program, the Nordic EMBL Partnership aims
-
the Norwegian Centre of Excellence Hybrid-technology-hub (HTH). Colourbox via Unsplash Colourbox More about the position NoPSC is dedicated to research on the chronic liver disease primary sclerosing
-
on building a gene editing platform that can be used to correct patient-specific mutations in ex vivo cell therapies for monogenic immune diseases. We use high-throughput biology techniques to optimize